1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Colorectal Cancer Therapeutics Market in APAC 2015-2019

Colorectal Cancer Therapeutics Market in APAC 2015-2019

  • December 2015
  • -
  • Infiniti Research Limited
  • -
  • 106 pages

About colorectal cancer
Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.

Technavio's analysts forecast the colorectal cancer therapeutics market in APAC to grow at a CAGR of 6.32% over the period 2014-2019.

Covered in this report
The report covers the current scenario and the growth prospects of the colorectal cancer therapeutics market in APAC for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of colorectal cancer. The colorectal cancer therapeutics market in APAC is segmented based on lines of chemotherapy: first-line chemotherapy and second-line chemotherapy.

Technavio's report, Colorectal Cancer Therapeutics Market in APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC; it also covers the landscape of the colorectal cancer therapeutics market in APAC and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
- APAC
- China
- Japan


Key vendors
- Amgen
- Bayer
- Bristol-Myers Squibb
- Chugai Pharmaceuticals
- Merck
- Sanofi

Other prominent vendors
- Accord Healthcare
- Advenchen Laboratories
- Aeterna Zentaris
- AstraZeneca
- AVEO Oncology
- Bavarian Nordic
- Biothera
- Boehringer Ingelheim
- Boston Biomedical
- Cancer Prevention Pharmaceuticals
- Celator Pharmaceuticals
- Daiichi Sankyo
- Debiopharm
- Eisai
- Eli Lilly
- EpicentRx
- GlaxoSmithKline
- Hutchison Medipharma
- Immodulon Therapeutics
- Immunomedics
- MacroGenics
- Merrimack Pharmaceuticals
- MolMed
- Mologen
- Morphotek
- Mylan
- Nektar Therapeutics
- Oncothyreon
- Otsuka Pharmaceutical
- PledPharma
- Precision Biologics
- PsiOxus Therapeutics
- Sun Pharmaceutical
- Symphogen
- Taiho
- Takeda
- Teva Pharmaceuticals
- ThromboGenics
- Xbiotech
- Yakult Honsha

Key market driver
- Increase in aging population
- For a full, detailed list, view our report

Key market challenge
- Unknown disease etiology
- For a full, detailed list, view our report

Key market trend
- Rise in public awareness
- For a full, detailed list, view our report


Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Table Of Contents

Colorectal Cancer Therapeutics Market in APAC 2015-2019
PART 01: Executive summary
- Highlights
- PART 02: Scope of the report
- Market overview
- Top-vendor offerings
- Vectibix
- PART 03: Product profiles
- Stivarga
- Erbitux
- Xeloda
- Avastin
- Zaltrap
- PART 04: Market research methodology
- Research methodology
- Economic indicators
- PART 05: Introduction
- Key market highlights
- PART 06: Disease overview
- Understanding the disease
- High risk factors
- Signs and symptoms
- Pathophysiology
- Diagnosis
- Staging
- Biomarker testing
- Epidemiology
- Treatment
- PART 07: Pipeline portfolio
- Information on pipeline candidates
PART 08: Market landscape
- Market overview
- Market size and forecast
- Colorectal cancer therapeutics market in Japan
- Colorectal cancer therapeutics market in China
- Five forces analysis
PART 09: Market segmentation by based on the type of molecules
- Small molecules
- Biologics
PART 10: Market segmentation by route of administration
- Oral
- Parenteral
PART 11: Market segmentation by lines of chemotherapy
- First-line chemotherapy
- Second-line chemotherapy
PART 12: Market drivers
PART 13: Impact of drivers
PART 14: Market challenges
PART 15: Impact of drivers and challenges
PART 16: Market trends
PART 17: Vendor landscape
- Competitive scenario
- Market share analysis 2014
- Other prominent vendors
- Amgen
PART 18: Key vendor analysis
- Bayer HealthCare
- Bristol-Myers Squibb
- Chugai Pharmaceutical
- Merck
- Sanofi
PART 19: Appendix
- List of abbreviations
PART 20: Explore Technavio
Exhibit 01: Product offerings 7
Exhibit 02: High risk factors for colorectal cancer
Exhibit 03: Signs and symptoms of colorectal cancer
Exhibit 04: Diagnostic tests for colorectal cancer
Exhibit 05: Staging for colon cancer
Exhibit 06: Staging for rectal cancer
Exhibit 07: Types of genes
Exhibit 08: Estimated incidence, mortality, and five-year prevalence per 100,000 in APAC 2012
Exhibit 09: Colorectal cancer mortality rates in APAC 2012 (rate per 100,000 population)
Exhibit 10: Incidence rates of colorectal cancer in Asia, 2011 (rate per 100,000 population)
Exhibit 11: Estimated incidence in adult population in APAC 2012
Exhibit 12: Colorectal cancer incidence and mortality rates in top seven countries in Asia regions, 2008, males
Exhibit 13: Colorectal cancer incidence and mortality rates in top seven countries in Asia regions, 2008, females
Exhibit 14: Treatment options for colorectal cancer
Exhibit 15: Types of surgical procedure for colorectal cancer
Exhibit 16: Types of radiation therapy for colorectal cancer
Exhibit 17: Types of targeted therapy
Exhibit 18: Summary of approved cancer drugs for colon cancer
Exhibit 19: Pipeline molecules for colorectal cancer
Exhibit 20: Colorectal cancer therapeutics market in APAC ($ billions)
Exhibit 21: Colorectal cancer therapeutics market in Japan 2014-2019 ($ billions)
Exhibit 22: Colorectal cancer therapeutics market in China 2014-2019 ($ millions)
Exhibit 23: Five forces analysis
Exhibit 24: Colorectal cancer therapeutics market in APAC segmented by molecule type
Exhibit 25: Colorectal cancer therapeutics market in APAC segmented by route of administration
Exhibit 26: Summary of chemotherapy drugs for the treatment of colorectal cancer
Exhibit 27: Use of branded targeted therapies in China and Japan 2013
Exhibit 28: Drivers of colorectal cancer therapeutics market in APAC
Exhibit 29: Impact of drivers
Exhibit 30: Challenges of colorectal cancer therapeutics market in APAC
Exhibit 31: Impact of drivers and challenges
Exhibit 32: Trends of colorectal cancer therapeutics market in APAC
Exhibit 33: Vectibix: YoY revenue and growth rate in Japan 2011-2013 ($ millions)
Exhibit 34: Amgen: Key takeaways
Exhibit 35: Bayer: Key takeaways
Exhibit 36: Bristol-Myers Squibb: Key takeaways
Exhibit 37: Avastin: YoY revenue and growth rate in Japan 2010-2014 ($ millions)
Exhibit 38: Xeloda: YoY revenue and growth rate in Japan 2010-2014 ($ millions)
Exhibit 39: Chugai Pharmaceutical: Key takeaways
Exhibit 40: Merck: Key takeaways
Exhibit 41: Sanofi: Key takeaways
Exhibit 42: Amgen: Business segmentation by revenue 2014
Exhibit 43: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 44: Amgen: Geographical segmentation by revenue 2014
Exhibit 45: Bayer HealthCare: Business segmentation by revenue 2014
Exhibit 46: Bayer HealthCare: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 47: Bayer HealthCare: Geographical segmentation by revenue 2014
Exhibit 48: Bristol-Myers Squibb: Products segmentation by revenue FY2014
Exhibit 49: Bristol-Myers Squibb: Revenue comparison by product segmentation by FY2013 and FY2014
Exhibit 50: Bristol-Myers Squibb: Geographical segmentation by FY2014 ($ millions)
Exhibit 51: Bristol-Myers Squibb: Revenue comparison by geographical segment by FY2013 and FY2014 ($ millions)
Exhibit 52: Chugai Pharmaceuticals: Business segmentation by revenue 2014 (therapeutics)
Exhibit 53: Chugai Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 54: Merck: Business segmentation by revenue 2014
Exhibit 55: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 56: Merck: Geographical segmentation by revenue 2014
Exhibit 57: Sanofi: Business segmentation by revenue 2014
Exhibit 58: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 59: Sanofi: Geographical segmentation by revenue 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.